Table 1.
Vaccines used for leishmaniasis
| Antigen | Disease | Vaccine type | Animal model | Result/Outcome | Reference No. (year) |
|---|---|---|---|---|---|
| Centrin deleted live parasite L. donovani | VL | Live (Genetically modified) | Dogs | Protection | [76] (2015) |
| Ascorbic acid-deficient live mutants of L. donovani | VL | Live (Genetically modified) | Mouse | Protection | [77] (2015) |
| Leishmania parasites lacking essential genes like dyhydrofolate reductase, biopterin reductase and cystein proteases | CL (L. max) | Live (Genetically modified) | Mouse | Partial protection | [79] (2015) |
| CL (L. m.) | |||||
| p27 gene knockout L. donovani parasites | VL (L. d.) | Live attenuated | Mouse | Protection | [82] (2013) |
| L. major (ALM) + BCG | VL & PKDL | Killed vaccine | Mouse | Partial protection | [5] (2006) |
| KBMA L. infantum and L. chagasi | VL | Killed vaccine | Mouse | Partial protection | [86] (2012) |
| Leishmune (FML) | VL (L. d.) | Fractioned vaccine | Dogs | Partial protection | [88] (2006) |
| KMP 11 | CL (L. m.) | Recombinant vaccine | Hamster | Protection | [94] (2005) |
| Leish F1 | VL (L. d.) | Recombinant protein | Clinical trial | Protection | [92, 93] (2011) |
| Leish 111f | VL (L. d.) | Recombinant vaccine | Mouse | Protection | [99] (2007) |
| HASPB1 | VL (L. d.) | Recombinant protein | Mouse | Partial protection | [95] (2000) |
| Leish-f1+MPL-SE | VL (L. I) | Recombinant vaccine | Clinical trial | Protection | [93] (2011) |
| rSMT | VL (L. d.) | Recombinant vaccine | Mouse | Protection | [102] (2007) |
| A2 | VL (L. i.) | Recombinant vaccine | Mouse | Partial protection | [101] (2009) |
| Leish-110f | VL (L. i) | Recombinant vaccine | Mouse | Protection | [98] (2009) |
| LD91+LD72+ LD51+LD31 | VL (L.d.) | Antigen cocktail vaccine | Mouse | Partial protection | [109] (2009) |
| (P-8 PGLC) | L. pifanoi | Antigen cocktail vaccine | Dog | Partial protection | [110] (2007) |
| rCDV-LACK, rCDV-TSA, and rCDV-LmSTI1 | CL (L. m.) | Antigen cocktail vaccine | Dog | Protection | [113] (2015) |
| Gp63 | VL (L.d.) | DNA vaccine | Mouse | Partial protection | [119] (2011) |
| TRYP | VL (L. i.) | DNA vaccine | Dog | Protection | [121] (2009) |
| NH36 | VL (L. d.) | DNA vaccine | Mouse | Partial protection | [123] (2009) |
| Proteophosphoglycans (PPGs) | VL (L. d.) | DNA vaccine | Hamster | Partial protection | [124] (2009) |
| ORFF | VL (L. d.) | DNA vaccine | Mouse | Partial protection | [127] (2009) |
| LPG 3 | VL (L. i.) | DNA vaccine | Mouse | Partial protection | [128] (2014) |
| LEISHDNAVAX | VL (L. i.) | DNA vaccine | Mouse | Protection | [130] (2015) |
Abbreviations: VL Visceral Leishmaniasis, CL Cutaneous Leishmaniasis, PKDL Post kala-azar dermal leishmaniasis, L.d. L. donovani, L.i., L. infantum, L.m. L.major, L.max, L. maxicana